{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF-only&page=2", "query": { "intervention": "MF-only", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF-only&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-10T19:22:12.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06150157", "title": "A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "JNJ-88549968", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-12-20", "completion_date": "2028-06-14", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 15, "location_summary": "Duarte, California • Aurora, Colorado • Tampa, Florida + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06150157" }, { "nct_id": "NCT02448381", "title": "FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cutaneous T-Cell Lymphoma" ], "interventions": [ { "name": "SGX301 (synthetic hypericin)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Soligenix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2015-12", "completion_date": "2020-11", "has_results": true, "last_update_posted_date": "2022-04-15", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02448381" }, { "nct_id": "NCT02576496", "title": "Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematological Malignancies", "Multiple Myeloma", "Hodgkin's Lymphoma", "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Tinostamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mundipharma Research Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2016-04-14", "completion_date": "2023-11-21", "has_results": false, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • New York, New York + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576496" }, { "nct_id": "NCT03227471", "title": "A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "VX-445", "type": "DRUG" }, { "name": "Matched Placebo", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "VX-561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2017-01-23", "completion_date": "2018-03-27", "has_results": true, "last_update_posted_date": "2022-01-18", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 26, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Madera", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03227471" }, { "nct_id": "NCT06590467", "title": "Abbott Structural Heart Device Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Diseases", "ASD - Atrial Septal Defect", "VSD - Muscular Ventricular Septal Defect", "PFO - Patent Foramen Ovale", "PIVSD - Post Infarct Muscular Ventricular Septal Defect", "Valvular Heart Disease" ], "interventions": [ { "name": "Amplatzer™ Occlusion Devices", "type": "DEVICE" }, { "name": "Epic™ Surgical Tissue Heart Valve devices", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2500, "start_date": "2024-08-21", "completion_date": "2039-11", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 13, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06590467" }, { "nct_id": "NCT04054245", "title": "PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis Transformation in Essential Thrombocythemia", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis" ], "interventions": [ { "name": "LOXL2 Inhibitor PAT-1251", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-07-24", "completion_date": "2019-07-24", "has_results": false, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04054245" }, { "nct_id": "NCT06834282", "title": "CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "CER-1236", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CERo Therapeutics Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 18, "start_date": "2025-04-07", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 5, "location_summary": "Sacramento, California • Denver, Colorado • Nashville, Tennessee + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834282" }, { "nct_id": "NCT03757039", "title": "Multifocal Visual Performance Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Presbyopia" ], "interventions": [ { "name": "Multifocal soft contact lenses", "type": "DEVICE" }, { "name": "Progressive addition lens spectacles", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "38 Years", "maximum_age": "58 Years", "sex": "ALL", "summary": "38 Years to 58 Years" }, "enrollment_count": 42, "start_date": "2018-12-16", "completion_date": "2019-03-06", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03757039" }, { "nct_id": "NCT03222609", "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2017-10-31", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222609" }, { "nct_id": "NCT02226172", "title": "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Glasdegib (PF-04449913)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-10-06", "completion_date": "2018-01-31", "has_results": true, "last_update_posted_date": "2019-01-17", "last_synced_at": "2026-09-10T19:22:12.356Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226172" } ] }